Here is the latest shareholding Pattern of SAMRAT PHARMA. For more details, see the SAMRAT PHARMA financial fact sheet and SAMRAT PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Mar-22 |
3
Jun-22 |
3
Sep-22 |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 49.65 | 49.65 | 49.54 | 48.64 | 48.64 | 48.64 | 48.64 | 48.64 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 49.65 | 49.65 | 49.54 | 48.64 | 48.64 | 48.64 | 48.64 | 48.64 | |
Mutual Funds | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Financial institution/Banks/Insurance | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Government | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FII | % | 0.00 | 3.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other | % | 3.24 | 0.00 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | |
Total Institution | % | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | |
Bodies Corporate | % | 6.02 | 7.55 | 7.45 | 7.76 | 6.92 | 6.57 | 2.67 | 2.25 | |
Individuals | % | 37.40 | 36.69 | 37.09 | 37.89 | 38.48 | 38.81 | 42.58 | 42.61 | |
NRIs/OCBs | % | 1.31 | 1.36 | 1.69 | 1.69 | 1.80 | 1.82 | 1.97 | 1.92 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 2.39 | 1.52 | 1.00 | 0.79 | 0.93 | 0.93 | 0.91 | 1.35 | |
Total Non-Institution | % | 47.12 | 47.12 | 47.23 | 48.13 | 48.13 | 48.13 | 48.13 | 48.13 | |
Total Public | % | 50.00 | 50.00 | 50.00 | 51.00 | 51.00 | 51.00 | 51.00 | 51.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Pharmaceuticals Company Shareholding Pattern: ZYDUS LIFESCIENCES CIPLA DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.